RECRUITING
I'm interested ...!!
HF Patients With LVADs Being Treated With SGLT2i
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
Conditions:
🦠 Heart Failure With Reduced Ejection Fraction
🗓️ Study Start (Actual) 8 September 2022
🗓️ Primary Completion (Estimated) September 2024
✅ Study Completion (Estimated) September 2024
👥 Enrollment (Estimated) 44
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE4
Locations:
📍 Chicago, Illinois, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • 1. LVAD implantation
    • 2. Have not already been prescribed management with an SGLT2i
    • 3. Estimated glomerular filtration rate (eGFR) ≥ 30 milliliters(ml)/minute(min)/1.73 meter(m)2
    • 4. Age ≥ 18 years-old
    • 5. Able to provide informed consent

    Exclusion Criteria:

    • 1. Diagnosis of Type 1 diabetes mellitus
    • 2. eGFR \< 30 ml/min/1.73 m2
    • 3. Age \< 18 years-old
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 4 March 2022
  • First Submitted that Met QC Criteria 4 March 2022
  • First Posted 15 March 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 18 December 2023
  • Last Update Posted 19 December 2023
  • Last Verified December 2023
I'm interested ...!!